Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00679770 · ClinicalTrials.gov registry record · Phase 2
Study of Different Doses of a Novel Treatment for Onychomycosis
A Phase 2 study of Distal, Subungual Onychomycosis, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 4
- Study locations
NCT00679770: Completed Phase 2 study of Distal, Subungual Onychomycosis, sponsored by Pfizer.
NCT00679770 is a Phase 2 study of Distal, Subungual Onychomycosis that has completed, run by Pfizer. The registered enrollment target is 28 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00679770, a Phase 2 study of Distal, Subungual Onychomycosis, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of the study is to determine the safety and efficacy of 2.5%, 5.0%, and 7.5% AN2690 Solutions compared to the vehicle alone in the treatment of distal, subungual onychomycosis of the great target toenail.
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG AN2690, 2.5%
- DRUG AN2690, 5%
- DRUG AN2690, 7.5%
Study Locations (4)
Texas
- DermResearch, Inc. - Austin
- J&S Studies - Bryan
- Endeavor Clinical Trials, PA & San Antonio Podiatry Associates, PC - San Antonio
New Mexico
- Academic Dermatology Associates - Albuquerque
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2006-06-30 |
| Est. Completion | 2007-08-31 |
| Phase | Phase 2 |
What the finished NCT00679770 record still lists
NCT00679770 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Distal, Subungual Onychomycosis appearing as the primary indexed condition, and to 4 interventions - of which Vehicle is the first listed.
NCT00679770 reports a single indexed study location in Texas, New Mexico.
Frequently Asked Questions
What is clinical trial NCT00679770 about?
NCT00679770 is a clinical study titled "Study of Different Doses of a Novel Treatment for Onychomycosis". The purpose of the study is to determine the safety and efficacy of 2.5%, 5.0%, and 7.5% AN2690 Solutions compared to the vehicle alone in the treatment of distal, subungual onychomycosis of the great target toenail.
What is the current status of trial NCT00679770?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2006-06-30. Estimated completion is 2007-08-31.
What conditions does trial NCT00679770 study?
This clinical trial studies the following conditions: Distal, Subungual Onychomycosis.
What interventions are being tested in trial NCT00679770?
The interventions under investigation include: Vehicle (DRUG), AN2690, 2.5% (DRUG), AN2690, 5% (DRUG), AN2690, 7.5% (DRUG).
Who is sponsoring clinical trial NCT00679770?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00679770 being conducted?
This trial has 4 study locations across New Mexico, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Distal, Subungual Onychomycosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00679770's enrollment target sits among peer trials
28 1677th of 2000 higher than 304 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI